Cidara Therapeutics Files 8-K on Officer/Director Changes
| Field | Detail |
|---|---|
| Company | Cidara Therapeutics, Inc. |
| Form Type | 8-K |
| Filed Date | Jun 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes, bylaws
Related Tickers: CDTX
TL;DR
CDTX filed an 8-K: new officers/directors elected, bylaws amended, and votes submitted. Big shakeup.
AI Summary
Cidara Therapeutics, Inc. filed an 8-K on June 18, 2025, reporting on several key events. These include the departure of directors or certain officers, the election of new directors, the appointment of certain officers, and updates to compensatory arrangements for officers. The filing also covers amendments to the company's articles of incorporation or bylaws, changes in its fiscal year, and the submission of matters to a vote of security holders. Additionally, it includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate governance and organizational changes at Cidara Therapeutics, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors, officers, and bylaws can signal shifts in strategy or internal dynamics that may affect the company's future performance.
Key Players & Entities
- Cidara Therapeutics, Inc. (company) — Registrant
- June 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-36912 (identifier) — SEC File Number
- 46-1537286 (identifier) — EIN
FAQ
Who are the specific directors or officers departing from Cidara Therapeutics?
The filing does not specify the names of the departing directors or officers, only that such departures are being reported.
Who were the newly elected directors or appointed officers?
The filing indicates the election of directors and appointment of officers but does not name the individuals involved.
What specific amendments were made to the Articles of Incorporation or Bylaws?
The filing states that amendments were made but does not detail the specific changes to the Articles of Incorporation or Bylaws.
What matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote but does not specify what those matters were.
Are there any details on the compensatory arrangements of certain officers mentioned in the filing?
The filing lists compensatory arrangements of certain officers as an item of information but does not provide specific details within the provided text.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 20, 2025 regarding Cidara Therapeutics, Inc..